7 reports

The molecules developed by Companies in Filing rejected/ Withdrawn, Phase II, IND/ CTA Filed and Preclinical stages are ##, ##, ## and ## respectively.

  • Antifungal
  • Pharmaceutical
  • United States
  • World
  • Product Initiative

##, ## ## ## ##, ##?

  • Antifungal
  • North America
  • World
  • Market Size
  • Merck & Co., Inc.

The company applies its drug delivery system technologies to develop novel dosage forms and delivery systems.

  • Antifungal
  • Infectious Disease
  • United States
  • Product Initiative
  • GlaxoSmithKline plc

Its products include nanoparticle injectable, transdermal patch, sublingual orally dissolving film and microsphere extended release injectable.

  • Antifungal
  • Infectious Disease
  • Neurology
  • United States
  • World

The company utilizes its core technologies such as transmucosal drug delivery, transdermal delivery, intra-vaginal delivery, topical and local delivery systems to develop pharmaceuticals and skin-care products.

  • Antifungal
  • Research And Development
  • United States
  • Product Initiative
  • SCYNEXIS, Inc.

TRANSDERMAL DELIVERY OF HYALURONIC ACID IS POSSIBLE USING A TECHNOLOGY COMBINING MICRODERMABRASION WITH A NOVEL ELECTROPHORETIC DELIVERY SYSTEM, THE ULTRAPEEL WITH TRANSDERMAL IONTO OFFERED BY MATTIOLI ENGINEERING.

  • Antifungal
  • World
  • Market Size
  • Galderma S.A.
  • Valeant Pharmaceuticals International, Inc.

Transdermal delivery of hyaluronic acid is possible using a technology combining microdermabrasion with a novel electrophoretic delivery system, the Ultrapeel with Transdermal Ionto offered by Mattioli Engineering.

  • Antifungal
  • Allergan plc
  • Galderma S.A.
  • Pfizer Inc.
  • Valeant Pharmaceuticals International, Inc.